Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage

Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, USA.
Transactions of the American Ophthalmological Society 12/2009; 107:146-58.
Source: PubMed


To determine the effects of the advanced glycation end product (AGE) cross-link breaker alagebrium on intraocular pressure (IOP), accommodation (ACC), outflow facility (OF), anterior segment morphology, and ocular AGE and receptors for AGE (RAGE) in older rhesus monkeys.
Six rhesus monkeys (aged 19 to 20 years) received 3 or 4 intracameral and intravitreal (final concentration, 1 mM) injections of alagebrium to one eye over 2.5 to 3 weeks and vehicle to the opposite eye. ACC and OF responses to intramuscular or intravenous pilocarpine were measured at baseline and at 1 to 2 weeks and 2, 4, and 6 months postinjection. IOP was measured prior to all injections, ACC, and OF measurements. Monkeys were euthanized 3 to 6 months after the last injection, the eyes were enucleated, and anterior and posterior segments were examined by electron microscopy or immunohistochemistry.
No significant differences were found in ACC or IOP at any time point after alagebrium treatment. Baseline OF was higher (37.0 +/- 6.0%; P < or = .005) in alagebrium-treated vs control eyes at 6 months postinjection. In 3 monkeys, alagebrium-treated eyes, compared to control eyes, showed greater focal plaque formation, similar to that seen in primary open-angle glaucoma, in the juxtacanalicular meshwork/inner wall of Schlemm's canal. No changes in anterior segment AGE or RAGE were detectable. However, some areas of the retina and optic nerve head exhibited decreased AGE and increased RAGE immunostaining.
Intraocular injection of AGE cross-link breakers is an unlikely approach for glaucoma therapy. However, it may generate a model for further study of glaucomatous-like plaque formation. Immunohistochemical changes in the posterior segment in response to alagebrium warrant further functional studies.

Download full-text


Available from: Elke Lütjen-Drecoll
  • Source

    Full-text · Article ·
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic nephropathy, retinopathy and accelerated atherosclerosis are a common cause of morbidity and premature mortality of people with diabetes, and a major economic cost to the healthcare system. In spite of widespread availability of intensive diabetes management approximately one in four people with diabetes develop clinically significant atherosclerotic or thrombotic events, over 60 % die of atherosclerosis-related diseases, and diabetes is a common cause of vision loss and renal impairment. Quantitative and qualitative changes in lipoproteins, such as nonenzymatic glycation, including early and late glycation, are likely to be contributory. Glycation of all major lipoprotein classes occurs and may promote micro- and macrovascular damage by various pathways including altered cellular handling by various cell types, increased oxidation, induction of inflammation, matrix binding and by pro-thrombotic effects. Lipoprotein glycation may contribute to residual vascular risk. Whilst difficult to quantify in a clinical setting lipoprotein glycation may represent a therapeutic target. Lipoprotein glycation can be reduced by optimizing glycemic control, which remains a therapeutic and practical challenge, and perhaps in the future may also be treated by effective anti-glycation agents.
    No preview · Chapter · Jan 2014